Abstract Details

Title Assessment of Relative Importance of Disease Modifying Treatment (DMT) Attributes in Multiple Sclerosis (MS) Patients

Topic Multiple Sclerosis

Presentation(s) P2 - (-)

Poster/Presentation
Number 366

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Tobias Sejbaek PRESENTER	Tobias Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Merck, Novartis, Roche, Sandoz and Sanofi. Tobias Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen, Merck, Novartis, Sanofi. The institution of Tobias Sejbaek has received research support from Biogen, Merck, Novartis, Roche and Sanofi.
	No disclosure on file
Jens Leander	No disclosure on file
Klaus G. Madsen	No disclosure on file